Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia (CLL).
I think in CLL over the past 5 years, we’re really starting to see a movement in using more of the small molecule inhibitors. There’s 5 that are FDA-approved at this point, using those as single agents but evolving to using that certainly more so in combination with immunotherapy, more in combination with chemoimmunotherapy. The data’s definitely evolving using those more at the upfront setting as opposed to the relapsed/refractory setting, as well as the ability to potentially stop those small molecule inhibitors once minimal residual disease, or MRD, achievement is attained. So that’s sort of where the data is currently evolving, but definitely using more of the oral chemotherapy options for patients.
To learn more, watch our Peer Exchange series on